Dupixent (Dupilumab)

Information about Dupixent

Dupixent is a monoclonal antibody that inhibits interleukin-4 (IL-4) and interleukin-13 (IL-13) signaling, which are key drivers of inflammation in various chronic allergic conditions. It is administered via subcutaneous injection and is indicated for multiple indications related to inflammatory conditions.

Product Highlights

• A targeted biologic medication designed to address underlying inflammation.
• Blocks both IL-4 and IL-13 pathways, which are involved in the immune response
• For patients with asthma not adequately controlled with standard therapies.
• To reduce nasal polyps and improve symptoms.
• For the treatment of moderate to severe eczema in adults and children.
• Approved for the treatment of this chronic allergic condition.

Key Ingredient

• Dupilumab

Key Benefits

• Reduces symptoms associated with asthma, eczema, and chronic rhinosinusitis.
• Helps patients achieve better control over their conditions, improving daily functioning.
• Provides sustained relief with regular administration, allowing for better management of chronic conditions.

Direction of Use

• Administered as a subcutaneous injection, typically once every two or four weeks, depending on the indication and patient response.
• Follow the instructions provided by a healthcare professional for proper preparation and injection technique.

Safety Concerns

• May include injection site reactions, headache, and conjunctivitis.
• Potential for allergic reactions; monitor for symptoms such as rash, itching, or difficulty breathing.
• As an immunomodulator, Dupixent may increase the risk of certain infections, so patients should be monitored closely.

Avoid Dupixent If

• If you have a known allergy to dupilumab or any component of the formulation.
• Patients with active or uncontrolled infections should avoid using Dupixent until the infection is resolved.
• Use may be not recommended for patients with severe liver impairment.

This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.